SIS
JAZZ icon

Sound Income Strategies’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sound Income Strategies’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$339 – 2663
2025
Q4 		$339 Hold
2
– – ﹤0.01% 2408
2025
Q3 		$276 Sell
2
-127
-98% -$15.2K ﹤0.01% 1582
2025
Q2 		$13.7K Hold
129
– – ﹤0.01% 853
2025
Q1 		$16K Buy
+129
New +$16.8K ﹤0.01% 771

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sound Income Strategies's JAZZ Position: Q1 2026 in Review

Sound Income Strategies sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2 shares — an estimated $339 sold.

Sound Income Strategies first reported a position in JAZZ in Q1 2025 and held it in 4 quarters. The position peaked at $16K in Q1 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Sound Income Strategies reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sound Income Strategies sold 2 Jazz Pharmaceuticals shares in Q1 2026, an estimated $339.
  • Sound Income Strategies first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Sound Income Strategies's Jazz Pharmaceuticals position peaked at $16K in Q1 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Sound Income Strategies's 13F filing for Q1 2026, filed 27 Apr 2026.